What is he best known for?
The fields of study he is best known for:
Thomas Litman mainly focuses on Molecular biology, ATP-binding cassette transporter, Biochemistry, Rhodamine 123 and Abcg2.
His Molecular biology research includes elements of Cell culture and Complementary DNA, Expressed sequence tag, cDNA library, Peptide sequence.
His ATP-binding cassette transporter study integrates concerns from other disciplines, such as P-glycoprotein, Antibody, Transitional epithelium and Pathology.
His study in the fields of ATPase, Gut flora and Gene expression under the domain of Biochemistry overlaps with other disciplines such as CCL3.
Thomas Litman has included themes like Endocrinology, Chemosensitizer, Efflux, Internal medicine and Chemosensitizing agent in his Rhodamine 123 study.
Within one scientific family, Thomas Litman focuses on topics pertaining to Multiple drug resistance under Abcg2, and may sometimes address concerns connected to Irinotecan, Camptothecin and Glucuronidation.
His most cited work include:
- Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes. (708 citations)
- From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance. (618 citations)
- The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2) (460 citations)
What are the main themes of his work throughout his whole career to date?
Thomas Litman mainly investigates microRNA, Cancer research, Biochemistry, Molecular biology and Immunology.
Thomas Litman interconnects Cancer, Breast cancer, Bioinformatics, Gene expression profiling and Computational biology in the investigation of issues within microRNA.
His Cancer research research also works with subjects such as
- Cutaneous T-cell lymphoma that intertwine with fields like IL-2 receptor,
- Lymphoma that intertwine with fields like Disease.
Thomas Litman combines topics linked to Biophysics with his work on Biochemistry.
The study incorporates disciplines such as Cell culture, Efflux, Rhodamine 123 and Western blot in addition to Molecular biology.
His research in ATP-binding cassette transporter intersects with topics in Multiple drug resistance and Drug resistance.
He most often published in these fields:
- microRNA (26.00%)
- Cancer research (23.33%)
- Biochemistry (16.67%)
What were the highlights of his more recent work (between 2018-2021)?
- Cancer research (23.33%)
- Mycosis fungoides (8.00%)
- Cutaneous T-cell lymphoma (8.00%)
In recent papers he was focusing on the following fields of study:
The scientist’s investigation covers issues in Cancer research, Mycosis fungoides, Cutaneous T-cell lymphoma, microRNA and Gene.
His studies deal with areas such as MHC class I, Estrogen receptor, STAT5, Lymphoma and Antibody as well as Cancer research.
His Mycosis fungoides research is multidisciplinary, relying on both Downregulation and upregulation, Transfection and Multicenter study.
The Downregulation and upregulation study which covers Cell that intersects with Immunology and Atopic dermatitis.
His research investigates the connection between microRNA and topics such as Epigenetics that intersect with issues in Tumor microenvironment and Disease.
His research on Gene frequently links to adjacent areas such as Computational biology.
Between 2018 and 2021, his most popular works were:
- Antibiotics inhibit tumor and disease activity in cutaneous T-cell lymphoma. (32 citations)
- Distinct immune phenotypes in infants developing asthma during childhood (10 citations)
- MicroRNAs in the Pathogenesis, Diagnosis, Prognosis and Targeted Treatment of Cutaneous T-Cell Lymphomas. (7 citations)
In his most recent research, the most cited papers focused on:
His primary scientific interests are in Cancer research, Psoriasis, Targeted therapy, Lymphoma and Atopic dermatitis.
His Cancer research research is multidisciplinary, incorporating elements of Gene knockdown, Oncogene, microRNA, STAT5 and Antibody.
Thomas Litman integrates microRNA and MCF-7 in his research.
His work on Psoriasis Area and Severity Index as part of general Psoriasis study is frequently connected to Secukinumab, therefore bridging the gap between diverse disciplines of science and establishing a new relationship between them.
His Targeted therapy research incorporates themes from Tumor microenvironment, Mycosis fungoides and Disease.
His Atopic dermatitis study combines topics from a wide range of disciplines, such as Precision medicine, Personalized medicine, Bioinformatics and Inflammatory pathways.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
